Ralio | $2,500,000 | (Apr 16, 2026)
Parasail | $32,000,000 | (Apr 16, 2026)
Certified by Founder
Lodge
Terremoto Biosciences
start up
United States
- South San Francisco, California
- 16/04/2026
- Series C
- $108,000,000
Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy. The company leverages the power of lysine-based covalency across the disease spectrum to develop both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Many of Terremoto’s founders helped establish this emergent area of science, with the intent to broaden the number of tractable targets and deliver medicines with superior therapeutic benefit. Terremoto is supported by leading investors OrbiMed and Third Rock Ventures. More information is available at www.terremotobio.com.
- Industry Biotechnology Research
- Website https://terremotobio.com/
- LinkedIn https://www.linkedin.com/company/terremoto-biosciences/
spektr | $20,000,000 | (Apr 16, 2026)
Modern Relay | $3,000,000 | (Apr 16, 2026)
Paxos Labs | $12,000,000 | (Apr 16, 2026)
Gitar | $9,000,000 | (Apr 16, 2026)
STORM Therapeutics Limited | $56,000,000 | (Apr 16, 2026)
Traza | $2,100,000 | (Apr 16, 2026)
Smartwage Società Benefit | $2,000,000 | (Apr 15, 2026)
Synera | $40,000,000 | (Apr 15, 2026)
Turion Space | $75,000,000 | (Apr 15, 2026)